Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $540,594.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 10,011 shares of the stock in a transaction on Friday, March 21st. The stock was sold at an average price of $54.00, for a total transaction of $540,594.00. Following the transaction, the director now directly owns 187,297 shares in the company, valued at $10,114,038. The trade was a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mona Ashiya also recently made the following trade(s):

• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The stock was sold at an average price of $54.02, for a total value of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34.

Disc Medicine Price Performance

Shares of Disc Medicine stock traded down $0.99 during trading on Friday, hitting $52.24. The company’s stock had a trading volume of 1,082,703 shares, compared to its average volume of 360,836. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -13.13 and a beta of 0.73. The stock has a 50-day moving average price of $55.26 and a two-hundred day moving average price of $56.02. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $68.73.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08. On average, equities analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its position in shares of Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after purchasing an additional 266 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock valued at $308,000 after buying an additional 396 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in shares of Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after acquiring an additional 503 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock worth $400,000 after purchasing an additional 593 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Disc Medicine in the fourth quarter valued at approximately $40,000. Institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IRON shares. Stifel Nicolaus lifted their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research note on Tuesday, January 21st. Scotiabank lifted their price objective on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 3rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Finally, Cantor Fitzgerald increased their price target on Disc Medicine from $99.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.